Small-Molecule Drugs in Immunotherapy

doi:10.2174/1389557522666220930154527

KIB OpenIR

	Small-Molecule Drugs in Immunotherapy
	Hao,Xuanrun; Chen,Zhongliang; Li,Haining; Wei,Minqin; Zuo,Zhili; Su,Qing
	2023
发表期刊	MINI-REVIEWS IN MEDICINAL CHEMISTRY
ISSN	1875-5607
卷号	23 期号:13 页码:1341-1359
摘要	Immunotherapy has been increasingly used in the treatment of cancer. Compared with chemotherapy, immunotherapy relies on the autoimmune system with fewer side effects. Small molecule immune-oncological medicines usually have good bioavailability, higher tissue and tumor permeability, and a reasonable half-life. In this work, we summarize the current advances in the field of small molecule approaches in tumor immunology, including small molecules in clinical trials and preclinical studies, containing PD1/PD-L1 small molecule inhibitors, IDO inhibitor, STING activators, ROR gamma t agonists, TGF-beta inhibitors, etc. PD-1/DP-L1 is the most attractive target at present. Some small molecule drugs are being in clinical trial studies. Among them, CA-170 has attracted much attention as an oral small molecule drug. IDO is another popular target after PD-1/PDL1. The dual IDO and PD-1 inhibitor can improve the low response of PD-1 and has a good synergistic effect. STING is a protein that occurs naturally in the human body and can enhance the body's immunity. ROR gamma t is mainly expressed in cells of the immune system. It promotes the differentiation of Th17 cells and produces the key factor IL-17, which plays a key role in the development of autoimmune diseases. TGF-beta signaling exhibits potent immunosuppressive activity on the coordinate innate and adaptive immunity, impairing the antitumor potential of innate immune cells in the tumor microenvironment. It is worth mentioning that immunotherapy drugs can often achieve better effects when used in combination, which will help defeat cancer.
关键词	Cancer immunotherapy inhibitors Pd-1/Pd-L1 inhibitor IDO inhibitor STING agonists ROR gamma t agonists TGF beta inhibitors INDOLEAMINE 2,3-DIOXYGENASE SIGNALING INHIBITOR DENDRITIC CELLS GROWTH TUMOR PATHWAY PEMBROLIZUMAB RECEPTORS DISCOVERY VADIMEZAN
DOI	10.2174/1389557522666220930154527
收录类别	SCI
WOS记录号	WOS:001041393600002
引用统计
文献类型	期刊论文
条目标识符	http://ir.kib.ac.cn/handle/151853/75533
专题	中国科学院昆明植物研究所
推荐引用方式 GB/T 7714	Hao,Xuanrun,Chen,Zhongliang,Li,Haining,et al. Small-Molecule Drugs in Immunotherapy[J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY,2023,23(13):1341-1359.
APA	Hao,Xuanrun,Chen,Zhongliang,Li,Haining,Wei,Minqin,Zuo,Zhili,&Su,Qing.(2023).Small-Molecule Drugs in Immunotherapy.MINI-REVIEWS IN MEDICINAL CHEMISTRY,23(13),1341-1359.
MLA	Hao,Xuanrun,et al."Small-Molecule Drugs in Immunotherapy".MINI-REVIEWS IN MEDICINAL CHEMISTRY 23.13(2023):1341-1359.

条目包含的文件		下载所有文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
1721872485_96245_167（29350KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	浏览下载